Replimune REPL
NASDAQ REPL
$23.28 +1.02 (+4.58%)
At close: Nov 10, 2026 · 4:00 PM EST

Replimune (REPL) FCF Margin (2017 - 2018)

Updated

Replimune (REPL) reported FCF Margin of -763.72% for fiscal Q3 2019 (quarter ended Dec 31, 2018), up 7676.91 percentage points from -8440.63% a year earlier and up 198.03 percentage points from the prior quarter.

Analysis

Replimune (REPL) FCF Margin (2017 - 2018) Analysis & Trends

Over the twelve months ended Dec 31, 2018, Replimune's FCF Margin came in at -1347.70%.

  • Year over year, FCF Margin has now increased in each of the last three quarters.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 33.69%
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 25.03%
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 41.97%
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 30.51%
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 38.60%
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 35.25%
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 57.81%
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 28.96%
10 Replimune 2.40 Bn 1.35 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 -763.72%
Sep 30, 2018 -961.75%
Jun 30, 2018 -3,072.69%
Dec 31, 2017 -8,440.63%
Sep 30, 2017 -36,940.00%
Jun 30, 2017 -18,420.00%
API Access

Replimune FCF Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=fcf-margin&ticker=REPL&period=max&api_key=YOUR_API_KEY